Merck & Co. Inc. (MRK) Social Stream

Featured Post From StockTwits About MRK

$IBRX what a steal at this price with bla months away! $sesn $mrk $bmy $labu

N-803 demonstrated promising results compared with other FDA-approved agents or investigational therapeutics in the space, such as pembrolizumab (Keytruda), which yielded a 41% CR rate at any time and a median duration of response of 16.2 months in responders.3 Similarly, nadofaragene firadenovec (rAd-IFNa/Syn3) elicited a 53% CR rate at any time with a median duration of response of 9.7 months.4

“N-803 had a smaller cohort, however, the CR rate at any time was much higher, at 71% compared with 41% and 53% for pembrolizumab and nadofaragene, [respectively],” https://www.urologytimes.com/view/novel-il-15-superagonist-n-803-hits-high-complete-response-rate-in-bcg-unresponsive-nmibc


Chamie reported. Our median duration was also favorable, although this must be taken within the context of a shorter median follow-up of 10.7 months. The cystectomy-free rate of 88% also compares favorably, with only 1 of 10 patients demonstrating extravesical disease.”